Care for patients with dyslipidemia is rapidly changing. While statins are typically the first therapy to be prescribed for dyslipidemia, many patients are candidates for additional or alternative treatments that lower LDL-C and Lp(a) levels, as many patients are unable to tolerate high statin doses. In fact, up to two-thirds of patients are unable to reach their lipid goals with statin therapy alone. There are also emerging therapies in late-stage clinical trials which target new molecules or molecular pathways, or which provide more convenient routes of administration such as oral rather than injectable. New guidelines have been updated for the treatment of patients after an acute coronary syndrome by ACC/AHA/NAEMSP/SCAI, which recommend non-statin lipid-lowering therapy for high-risk patients if they are already on the maximal tolerated dose of statin therapy and their LDL-C levels remain ≥50 mg/dL for high-risk patients. Deciding which non-statin therapy to add to a patient’s background regimen depends on several factors, and not all clinicians may be aware of the most recent clinical trial data and current guidelines for the treatment of dyslipidemia.
In this program, Drs. Cannon, Bhatt, and O'Donoghue review the current status of and evidence supporting various non-statin approaches to dyslipidemia, and later this fall will supplement this discussion with an update from new data presented at ESC2025.
Cardiologists, lipidologists, and other healthcare providers who care for patients with dyslipidemia
Review updated pathophysiology of atherosclerosis, lipid science, current guidelines, and novel therapeutic targets to lower LDL-C and Lp(a) for patients with dyslipidemia
Analyze and contextualize newer clinical trial data for therapies to lower LDL-C levels as presented at ESC2025
Discuss how to utilize combinations of lipid-lowering therapies to improve long term outcomes for dyslipidemia patients with atherosclerosis
a. Pathophysiologyb. Long Term Effects of Elevated LDL-C and Lp(a)c. Barriers to Achieving LDL-C Goals
a. Evidence for Guidelines Adherence Improves Patient Outcomesb. ESC Guidelinesc. ACC/AHA Guidelinesd. NLA Guidelines
a. Oral PCSK9b. Ezetimibec. Bempedoic Acid
a. A Data Update to Support Managing Healthy LP(a) Levelsb. Should LP(a) be Included in Lipid Panel Laboratory Testingc. Emerging Therapeutic Approaches to Lower LP(a)
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Christopher P. Cannon, MD (Course Chair) | Consultant/Advisor: Amgen Inc; Amryt Pharma; Ascendia Pharmaceutical Solutions; Biogen; Boehringer Ingelheim International GmbH; CHIESI Farmaceutici S.p.A.; CSL Behring; Genomadix; Janssen Pharmaceuticals, Inc; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC; Milestone Pharmaceuticals USA, Inc; Novartis AG; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc. Grant/Research Support: Amgen Inc; Areteia Therapeutics, Inc; Better Therapeutics Inc; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Novo Nordisk A/S; ROMTherapy, Inc. |
| Deepak L. Bhatt, MD, MPH, MBA | Advisory Board: Angiowave; Antlia Bioscience; Bayer AG; Boehringer Ingelheim International GmbH; CellProthera; Cereno Scientific; E-Star Biotech; High Enroll; Janssen Pharmaceuticals, Inc, Level Ex; McKinsey; Merck & Co., Inc.; NirvaMed; Novo Nordisk A/S; Repair Biotechnologies; Stasys; Tourmaline Bio Board of Directors: Angiowave (Stock Options); Bristol Myers Squibb (Stock); DRS.LINQ (Stock Options); High Enroll (Stock) Consultant: Alnylam; Altimmune; Broadview Ventures; Corcept Therapeutics; Corsera; GlaxoSmithKline; Hims; SERB; SFJ; Summa Therapeutics; Worldwide Clinical Trials Data Monitoring Committees: Acesion Pharma; Assistance Publique-Hôpitaux de Paris; Baim Institute for Clinical Research; Boston Scientific (Chair, PEITHO Trial); Contego Medical (Chair, PERFORMANCE 2); Novartis; Population Health Research Institute Honoraria: Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring); Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees); CSL Behring (AHA lecture); Philips (Becker's Webinar on AI); Population Health Research Institute Research Funding: Abbott; Acesion Pharma; Afimmune; Alnylam; Amarin; Amgen; AstraZeneca; Atricure; Bayer AG; Boehringer Ingelheim International GmbH; Boston Scientific; CellProthera; Cereno Scientific; Chiesi; Cleerly; CSL Behring; Faraday Pharmaceuticals; Fractyl; Idorsia; Janssen Pharmaceuticals, Inc; Javelin; Lexicon; Lilly; Medtronic; Merck & Co., Inc.; MiRU; Moderna; Novartis AG; Novo Nordisk A/S; Pfizer; PhaseBio; Regeneron; Roche; Sanofi; Stasys; 89Bio Site Co-Investigator: Cleerly |
| Michelle L. O'Donoghue, MD, MPH | Consultant/Advisor: Amgen Inc; AstraZeneca; Janssen Pharmaceuticals, Inc; NewAmsterdam Pharma; Novartis AG; Novo Nordisk A/S; Verve Therapeutics, Inc. Grant/Research Support: Amgen Inc; AstraZeneca; Marea Therapeutics, Inc.; Novartis AG |
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC, Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Merck & Co., Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
